BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) SVP Chan Lee sold 1,115 shares of BeOne Medicines stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $375.00, for a total value of $418,125.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Chan Henry Lee also recently made the following trade(s):
- On Tuesday, August 11th, Chan Lee sold 2,666 shares of BeOne Medicines stock. The shares were sold at an average price of $360.00, for a total value of $959,760.00.
- On Thursday, July 30th, Chan Lee sold 1,044 shares of BeOne Medicines stock. The stock was sold at an average price of $323.69, for a total value of $337,932.36.
- On Wednesday, July 8th, Chan Lee sold 664 shares of BeOne Medicines stock. The stock was sold at an average price of $302.46, for a total transaction of $200,833.44.
BeOne Medicines Trading Down 0.2%
Shares of ONC traded down $0.70 during midday trading on Friday, hitting $358.07. The stock had a trading volume of 474,002 shares, compared to its average volume of 306,091. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The firm has a market cap of $39.31 billion, a PE ratio of 63.04 and a beta of 0.61. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.40 and a quick ratio of 3.06. The stock’s 50 day moving average is $353.31 and its 200 day moving average is $315.93.
Analyst Upgrades and Downgrades
ONC has been the topic of several recent analyst reports. Truist Financial increased their price target on BeOne Medicines from $416.00 to $418.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings raised BeOne Medicines from a “sell (d-)” rating to a “hold (c+)” rating in a research report on Tuesday, September 22nd. Zacks Research upgraded BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Friday, August 7th. Guggenheim lifted their target price on BeOne Medicines from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, TD Cowen boosted their target price on shares of BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $404.14.
Trending Headlines about BeOne Medicines
Here are the key news stories impacting BeOne Medicines this week:
- Positive Sentiment: JPMorgan raised its price target on BeOne Medicines to $445 from $425 and maintained an “overweight” rating, implying substantial upside from recent levels. This reinforces the broader Wall Street consensus, which remains “Buy.” JPMorgan raises BeOne Medicines price target
- Positive Sentiment: Investor’s Business Daily said BeOne shares are approaching potential buy points, highlighting continued momentum in BRUKINSA, the company’s blockbuster cancer drug, which generated $1.2 billion in second-quarter sales. BeOne Medicines poised to hit early buy points
- Neutral Sentiment: BeOne’s latest quarterly results exceeded expectations, with earnings of $2.05 per share versus a $1.40 consensus estimate and revenue of $1.71 billion versus $1.66 billion. Analysts expect approximately $8.81 in full-year earnings per share, although the stock’s valuation remains elevated at more than 60 times earnings.
- Negative Sentiment: Insider Xiaodong Wang sold 31,028 shares for approximately $11.3 million, reducing his direct ownership by 50%. Separately, Senior Vice President Chan Lee sold 1,115 shares for about $418,000. Both transactions were executed under pre-arranged Rule 10b5-1 plans, which lessens—but does not eliminate—their significance as a sentiment signal. BeOne Medicines insider sales
Institutional Trading of BeOne Medicines
A number of large investors have recently modified their holdings of ONC. Global Retirement Partners LLC increased its holdings in BeOne Medicines by 1,051.7% during the 4th quarter. Global Retirement Partners LLC now owns 334 shares of the company’s stock worth $101,000 after purchasing an additional 305 shares during the period. Parallel Advisors LLC lifted its holdings in shares of BeOne Medicines by 24.0% in the 1st quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock worth $104,000 after buying an additional 68 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of BeOne Medicines by 16.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock worth $110,000 after buying an additional 52 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of BeOne Medicines during the 1st quarter worth $201,000. Finally, Empowered Funds LLC purchased a new position in shares of BeOne Medicines during the first quarter valued at $201,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.
BeOne Medicines Company Profile
BeOne Medicines Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for people with cancer. The company operates across the research and development, clinical testing, regulatory and commercial stages of the biopharmaceutical industry, with an emphasis on treatments for blood cancers and solid tumors.
Its marketed portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat several B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy targeting the PD-1 pathway for certain cancers.
Featured Articles
- Five stocks we like better than BeOne Medicines
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
